Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at ACR Meeting

Abstract:
The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class of pain medicines will be reported November 7th at the annual meeting of the American College of Rheumatology (ACR) in Chicago.

Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at ACR Meeting

Philadelphia, PA | Posted on November 4th, 2011

The data result from a broad development effort using a proprietary nanotechnology to re-formulate certain products in the large class of pain medicines called NSAIDs (non-steroidal anti-inflammatory drugs). Nano-formulations reduce drug particle size and enhance drug dissolution in the body.

The objective is to lower the dosing of NSAIDs and thus improve their safety and tolerability while maintaining their effectiveness. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both have advised that NSAIDs should be administered at the lowest effective dose for the shortest duration consistent with treatment goals.1,2

Iroko has initiated its Phase 3 program.

At the ACR meeting, the Phase 2 results will be the subject of three presentations:

Application of Nanotechnology to Improve Non-Steroidal Anti-Inflammatory Drugs
(Presentation Number: 1282)
A Phase 2 Study Evaluating the Acute Pain Relief of a Nano-Formulated Oral Naproxen
(Presentation Number: 1281)
Acute Pain Relief by a Proprietary, Nano-Formulated Lower-Dose Oral Indomethacin
(Presentation Number: 1280)

The presentations will be made on November 7th from 9:00-11:00 AM in the F2 Poster Hall at the McCormick Place Convention Center.

Nano-formulations
Iroko formulates NSAIDs using the proprietary SoluMatrix™ nanotechnology platform of its partner, iCeutica. These product candidates are intended for administration at lower doses without compromising onset of action and effectiveness, in keeping with the public-health advisories of the FDA and the EMA.

####

About Iroko Pharmaceuticals, LLC
Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops and maximizes the potential of currently marketed products on a global basis through focused selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient treatment.

1Public Health Advisory – FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDS). July 7, 2005.

2Opinion of the Committee for Medicinal Products for Human Use Pursuant to Article 5(3) of Regulation (EC) No 726/2004, for Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDS). October 18, 2006.

For more information, please click here

Contacts:
Phoenix IP Ventures
Lisa Gray
Managing Partner
267-765-3233

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

National Space Society Congratulates SpaceX on the Falcon 9's Return to Flight January 19th, 2017

Eric Berger Wins the National Space Society's 2017 Space Pioneer Award for Mass Media January 19th, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Nanomedicine

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017

Keystone Nano Announces FDA Approval Of Investigational New Drug Application For Ceramide NanoLiposome For The Improved Treatment Of Cancer January 10th, 2017

Captured on video: DNA nanotubes build a bridge between 2 molecular posts: Research may lead to new lines of direct communication with cells January 9th, 2017

Announcements

National Space Society Congratulates SpaceX on the Falcon 9's Return to Flight January 19th, 2017

Eric Berger Wins the National Space Society's 2017 Space Pioneer Award for Mass Media January 19th, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Events/Classes

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016

Imec and Holst Centre Introduce World’s First Solid-State Multi-Ion Sensor for Internet-of-Things Applications December 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project